Comparative Pharmacology
Head-to-head clinical analysis: BENTYL versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENTYL versus LUSEDRA.
BENTYL vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicyclomine is a muscarinic acetylcholine receptor antagonist that blocks the action of acetylcholine at postganglionic parasympathetic effector sites, reducing gastrointestinal smooth muscle spasms and hypermotility.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
20 mg orally four times daily; may increase to 40 mg four times daily if tolerated. Immediate-release: 20 mg orally every 6 hours. Extended-release: 20 mg orally twice daily.
5 mg orally once daily.
None Documented
None Documented
1.9 to 3 hours (terminal elimination half-life); clinical context: short half-life supports multiple daily dosing for spasm relief.
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Primarily renal (approximately 60% as unchanged drug and metabolites) and fecal (about 40% via biliary elimination).
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category C
Category C
Anticholinergic
Anticholinergic